CV Sciences, Inc. - 8-K Filing

CV Sciences reports Q3 2026 revenue of $3.0 million with positive adjusted EBITDA of $32,000 despite a net loss of $93,000.

SEC EDGAR · November 12, 2026, 21:03 UTC

Tickers: $CVSI

More Regulatory news

Stark Novus Financial Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:44 UTC
Starling Oncology, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:43 UTC
Spero Therapeutics, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:43 UTC
BATTALION OIL CORP - 10-Q Filing SEC EDGAR · November 12, 2026, 21:43 UTC
INNOVATIVE FOOD HOLDINGS INC - 10-Q Filing SEC EDGAR · November 12, 2026, 21:42 UTC
Silexion Therapeutics Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 21:42 UTC
DiaMedica Therapeutics Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:42 UTC
BATTALION OIL CORP - 8-K Filing SEC EDGAR · November 12, 2026, 21:41 UTC
Algorhythm Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:42 UTC
AMERICAN BATTERY MATERIALS, INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:41 UTC